Company Overview of Zacharon Pharmaceuticals, Inc.
Zacharon Pharmaceuticals, Inc. operates in research and development of molecules that target pathways of glycan and glycolipid metabolism. It offers ZP103, which is an anti-metastatic glycan inhibitor. The company has a strategic research collaboration with Pfizer Inc. to develop drugs for orphan diseases, that include lysosomal storage disorders. Zacharon Pharmaceuticals, Inc. was incorporated in 2001 and is based in San Diego, California. As of January 4, 2013, Zacharon Pharmaceuticals, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
5626 Oberlin Drive
San Diego, CA 92121
Founded in 2001
Key Executives for Zacharon Pharmaceuticals, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Zacharon Pharmaceuticals, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.